MedWatch

Eargo stock surged following OTC rules reveal

The first over-the-counter sales of hearing aids in the US will be possible in October, and some firms are expected to do well in this new space.

Photo: Eargo / PR

On Tuesday after the US Food and Drug Administration (FDA) revealed the final rule set for the upcoming over-the-counter sales channel for hearing aids, Eargo, a US-based hearing firm, soared 77% on the stock exchange, bringing its share price up to USD 2.02.

According to Bloomberg News, Eargo was a supporter of the proposed regulation, and had backed it publicly in a comment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs